Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition

Apr 09 2018

• By Joseph Haas

Businessman touched r and d sign. R d icon network business concept word cloud background tag. R&D: Research and development word lettering typography design illustration with line icons and ornaments

Related Content

Genfit May Be Gaining An Edge In NASH Race

Oct 26 2017

The NASH Pipeline: Replete With Targets And New Compounds

Aug 29 2016

Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements

Nov 03 2017

Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs

Mar 22 2018

AstraZeneca and Isis broaden antisense deal

Aug 03 2015

Related Companies

AstraZeneca PLC

Ionis Pharmaceuticals, Inc.

Eli Lilly and Company

Terns Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Gilead Sciences, Inc.

Allergan plc

Takeda Pharmaceutical Co. Ltd.

Novartis AG

Bristol Myers Squibb Company

Boehringer Ingelheim GmbH

Novo Nordisk A/S

Pfizer Inc.

Takeda Pharmaceutical Co. Ltd.

Merck & Co., Inc.

Enanta Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc.

Additional Topics

Deals Research & Development Business Strategies Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.